Editorial
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World Journal of Experimental Medicine. Aug 30, 2018; 8(1): 1-7
Published online Aug 30, 2018. doi: 10.5493/wjem.v8.i1.1
Predictive markers of endocrine response in breast cancer
Duniya Mosly, Arran Turnbull, Andrew Sims, Carol Ward, Simon Langdon
Duniya Mosly, Arran Turnbull, Andrew Sims, Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research Centre, MRC Institute of Genetics and Molecular Medicine, Edinburgh EH4 2XR, United Kingdom
Duniya Mosly, Arran Turnbull, Carol Ward, Simon Langdon, Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom
Carol Ward, the Royal (Dick) School of Veterinary Studies and Roslin Institute, University of Edinburgh, Easter Bush, Roslin, Midlothian, Edinburgh EH25 9RG, United Kingdom
Author contributions: All authors contributed their views in this editorial; all authors read and agreed to the final manuscript.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Simon Langdon, PhD, Reader (Associate Professor), Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, United Kingdom. simon.langdon@ed.ac.uk
Telephone: +44-131-5371763 Fax: +44-131-5373159
Received: June 29, 2018
Peer-review started: June 30, 2018
First decision: July 17, 2018
Revised: July 26, 2018
Accepted: August 4, 2018
Article in press: August 4, 2018
Published online: August 30, 2018
Processing time: 62 Days and 17.5 Hours
Core Tip

Core tip: The expression level of estrogen receptor remains the major determinant of response for endocrine therapy in breast cancer. Molecular signatures provide increasing confidence for helping identify breast cancers for which endocrine therapy alone is likely to be sufficient. Estrogen and proliferation related genes have come to the fore in many of the molecular signatures. In neo-adjuvant studies, Ki67 expression at baseline and after 2 wk treatment can provide useful prognostic and predictive information. Neo-adjuvant studies continue to seek new markers that relate to tumor response.